Beta cell function in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2 year double-blind randomised controlled study

被引：0
|
作者：
Johansen, O. [1 ]
Boehm, B. [2 ]
Grill, V. [3 ]
Torjesen, P. A. [4 ]
Bhattacharya, S. [5 ]
Patel, S. [6 ]
Wetzel, K. [5 ]
Woerle, H. -J. [7 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Asker, Norway
[2] Univ Ulm, D-89069 Ulm, Germany
[3] Norwegian Univ Sci & Technol, N-7034 Trondheim, Norway
[4] Aker Univ Hosp, Oslo, Norway
[5] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[6] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
[7] Boehringer Ingelheim KG, Ingelheim, Germany
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
148
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [21] A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults
    Halvorsen, Yuan-Di
    Lock, John Paul
    Frias, Juan P.
    Tinahones, Francisco Jose
    Dahl, Dominik
    Conery, Annie L.
    Freeman, Mason W.
    DIABETES OBESITY & METABOLISM, 2023, 25 (01): : 293 - 301
  • [22] Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study
    Zhao, Xin
    Sun, Jing
    Zhang, Zhihua
    Chen, Miao
    Gong, Tiejun
    He, Guangsheng
    Li, Yingmei
    Liu, Hong
    Li, Fei
    Li, Xin
    Zhou, Hu
    Wang, Xiaoqin
    Hong, Mei
    Lei, Lei
    Yin, Hongyan
    Luo, Xian
    Li, Yang
    Fan, Songhua
    Guo, Xiaojun
    Shi, Michael M.
    Su, Weiguo
    Zhang, Liansheng
    Han, Bing
    Zhang, Fengkui
    LANCET HAEMATOLOGY, 2025, 12 (02): : e97 - e108
  • [23] BARICITINIB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Wallace, D. J.
    Furie, R. A.
    Tanaka, Y.
    Kalunian, K. C.
    Mosca, M.
    Petri, M. A.
    Dorner, T.
    Cardiel, M. H.
    Bruce, I. N.
    Gomez, E.
    Carmack, T.
    Janes, J. M.
    Linnik, M. D.
    Silk, M.
    Hoffman, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 59 - 59
  • [24] Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
    Haak, T.
    Meinicke, T.
    Jones, R.
    Weber, S.
    von Eynatten, M.
    Woerle, H. -J.
    DIABETES OBESITY & METABOLISM, 2012, 14 (06): : 565 - 574
  • [25] Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
    Verstovsek, Srdan
    Gerds, Aaron T.
    Vannucchi, Alessandro M.
    Al-Ali, Haifa Kathrin
    Lavie, David
    Kuykendall, Andrew T.
    Grosicki, Sebastian
    Iurlo, Alessandra
    Goh, Yeow Tee
    Lazaroiu, Mihaela C.
    Egyed, Miklos
    Fox, Maria Laura
    McLornan, Donal
    Perkins, Andrew
    Yoon, Sung -Soo
    Gupta, Vikas
    Kiladjian, Jean -Jacques
    Granacher, Nikki
    Lee, Sung-Eun
    Ocroteala, Luminita
    Passamonti, Francesco
    Harrison, Claire N.
    Klencke, Barbara J.
    Ro, Sunhee
    Donahue, Rafe
    Kawashima, Jun
    Mesa, Ruben
    LANCET, 2023, 401 (10373): : 269 - 280
  • [26] Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial
    Wittert, Gary
    Atlantis, Evan
    Grossmann, Mathis
    Yeap, Bu B.
    Conway, Ann
    Stuckey, Bronwyn
    Handelsman, David
    McLachlan, Robert
    Allan, Carolyn
    Jenkins, Alicia
    Daniel, Mark
    Bracken, Karen
    CLINICAL ENDOCRINOLOGY, 2018, 89 : 47 - 48
  • [27] Increase in beta cell function and improvement in HOMA-2beta index induced by saxagliptin in patients with latent autoimmune diabetes in adults
    Buzzetti, R.
    Pozzilli, P.
    Frederich, R.
    Iqbal, N.
    Hirshberg, B.
    DIABETOLOGIA, 2014, 57 : S355 - S355
  • [28] Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial
    Ross, Stuart A.
    Rafeiro, Elizabeth
    Meinicke, Thomas
    Toorawa, Robert
    Weber-Born, Sonja
    Woerle, Hans-Juergen
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (09) : 1465 - 1474
  • [29] Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial
    Kim, Yonghyun
    Kang, Eun Seok
    Jang, Hak Chul
    Kim, Dong Jun
    Oh, Taekeun
    Kim, Eun Sook
    Kim, Nan-Hee
    Choi, Kyung Mook
    Kim, Sung-Rae
    You, JiYoung
    Kim, Se-Jin
    Lee, Moon-Kyu
    DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 631 - 639
  • [30] Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial
    Kraaijenhof, Jordan
    Muskiet, Marcel H. A.
    Tonneijck, Lennart
    Ouwens, D. Margriet
    Kramer, Mark H. H.
    van Raalte, Daniel H.
    Smits, Mark M.
    DIABETES OBESITY & METABOLISM, 2020, 22 (10): : 1847 - 1856
12345